Composition having bradycardia-improving and atrioventricular block-improving effects

Acerola and isoproterenol synergistically improve bradycardia and atrioventricular block effects, addressing side effects and cost issues in existing treatments by enhancing efficacy with lower isoproterenol doses.

JP7946320B2Active Publication Date: 2026-11-09NIPPON MENARD COSMETIC CO
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2022192028
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2022-11-30
Publication Date
2026-11-09
Estimated Expiration
2042-11-30

AI Technical Summary

Technical Problem

Existing treatments for bradycardia and atrioventricular block using isoproterenol suffer from significant side effects and high costs due to non-selective adrenergic receptor agonism, necessitating a composition that enhances efficacy while minimizing side effects and reducing drug doses.

Method used

A composition combining acerola, a plant from the Malpighiaceae family, with isoproterenol to synergistically enhance bradycardia and atrioventricular block effects, allowing for a lower dose of isoproterenol and reducing side effects.

Benefits of technology

The combination of acerola and isoproterenol exhibits enhanced bradycardia and atrioventricular block effects, achieving similar therapeutic outcomes with reduced isoproterenol dosage, thereby minimizing side effects and costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007946320000001
    Figure 0007946320000001
Patent Text Reader

Abstract

To provide a composition having excellent bradycardia improving effect and atrioventricular block improving effect.SOLUTION: Combining acerola with isoproterenol showed a particularly significant effect of improving bradycardia and atrioventricular block compared to acerola or isoproterenol alone. That is to say, by combining acerola with isoproterenol, acerola enhances the effect of isoproterenol, allowing a low dose of isoproterenol to exert the same effect. Therefore, a composition containing acerola and isoproterenol can be used as a food, quasi-drug, or pharmaceutical product that has excellent bradycardia improving effect and atrioventricular block improving effect.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD

[0001] The present invention relates to a composition having a bradycardia-improving action and an atrioventricular block-improving action, characterized by containing acerola and isoproterenol.

BACKGROUND ART

[0002] Isoproterenol (isoprenaline) is a pharmaceutical agent that has cardiopulmonary function-improving actions such as enhancing the contractile force of the heart and increasing heart rate, and is used for the treatment of bradycardia and atrioventricular block. On the other hand, it has a serious side effect of lowering serum potassium level.

[0003] Its mechanism of action is known to be non-selective adrenergic receptor agonism (Non-Patent Document 1). Since the mechanism of action for improving bradycardia and atrioventricular block is adrenergic receptor agonism, the potency of the bradycardia and atrioventricular block-improving action can be evaluated using adrenergic receptor agonism as an indicator. Furthermore, as indicators of adrenergic receptor agonism, factors whose production is promoted by adrenergic receptor agonism, such as Peroxisome proliferative activated receptor gamma coactivator 1 alpha (PGC1α) and Fibronectin Type III Domain Containing 5 (FNDC5), can be used.

[0004] An invention that obtains the pharmacological activity required for treatment at a low dose is extremely beneficial in terms of reducing the risk of drug side effects and cutting down on annually increasing drug costs. As a result of intensive studies, the present inventors have found that a combination of acerola, a plant belonging to the Malpighiaceae family, and isoproterenol exhibits excellent bradycardia-improving action and atrioventricular block-improving action. Therefore, by combining acerola with isoproterenol, acerola enhances the action of isoproterenol, and the same level of effect can be exerted with a low dose of isoproterenol.

[0005] While the effectiveness of acerola (Barbados cherry, Malpighia emarginata DC.), used in the present invention, has been reported in blood glucose elevation inhibitors containing acerola extract (Patent Document 1), its effects on improving bradycardia or atrioventricular block are completely unknown. [Prior art documents] [Patent Documents]

[0006] [Patent Document 1] Patent No. 4451627 [Non-patent literature]

[0007] [Non-Patent Document 1] Acute Med Surg., Vol.4(3):353-357(2017) [Overview of the project] [Problems that the invention aims to solve]

[0008] The present invention relates to a composition having bradycardia-improving and atrioventricular block-improving effects, characterized by containing acerola and isoproterenol. [Means for solving the problem]

[0009] As a result of diligent research, the inventors of this invention have found that acerola and isoproterenol have excellent bradycardia-improving and atrioventricular block-improving effects.

[0010] The acerola used in this invention can be Malpighia emarginata DC., a species of the Malpighiaceae family. The part of the acerola used in this invention is not particularly limited, but examples include the fruit, leaves, seeds, and bark, and the fruit is particularly preferred.

[0011] The acerola used in this invention can be used as is, or, if necessary, processed by juicing, drying, crushing, or shredding can be used. Furthermore, the acerola can be used as an extract, and the extraction solvent can be water, lower alcohols (ethanol, methanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, etc.), liquid polyhydric alcohols (1,3-butylene glycol, propylene glycol, glycerin, etc.), ketones (acetone, methyl ethyl ketone, etc.), acetonitrile, esters (ethyl acetate, butyl acetate, etc.), hydrocarbons (hexane, heptane, petroleum ether, etc.), ethers (ethyl ether, tetrahydrofuran, propyl ether, etc.), etc. These solvents may be used individually or in mixtures of two or more. In this invention, it is preferable to use the juice obtained by squeezing the fruit of the acerola.

[0012] Acerola may be used as is after the above processing or extraction, or it may be used after processing such as concentration, dilution, filtration, decolorization with activated carbon, deodorization, or ethanol precipitation as needed. Furthermore, the extracted solution may be processed by concentration to dryness, spray drying, or freeze-drying and used as a dried product.

[0013] The amount of acerola used in this invention can be appropriately adjusted depending on the administration method, purpose of use, age, body weight, etc. For adults, the daily intake of acerola can be 0.05 to 3000 mg, preferably 10 to 2000 mg, of acerola fruit juice powder or acerola fruit extract, taken orally once to several times a day. In some cases, a smaller amount than the above range may be sufficient, while in other cases, it may be necessary to consume more than the range. Furthermore, the method of adding the pharmacoactive ingredient during formulation can be either added beforehand or during manufacturing; the appropriate method should be chosen based on workability.

[0014] In this invention, isoproterenol (also known as isoprenaline, (RS)-4-"1-hydroxy-2-(isopropylamino)ethyl"benzene-1,2-diol) can be any product available on the market. As a pharmaceutical drug, it is used at a dose of 35-55 mg per day, adjusted as appropriate depending on age and symptoms, but in this invention, it can be used at a lower dose by combining it with acerola. Isoproterenol hydrochloride can also be used as a substitute.

[0015] The present invention provides a composition containing acerola and isoproterenol, which has bradycardia-improving and atrioventricular block-improving effects, and can be used as a food, quasi-drug, or pharmaceutical. As a food, it can be used in the form of tablets, soft capsules, hard capsules, granules, gummies, beverages, jellies, etc. As a quasi-drug or pharmaceutical, it can be used as oral capsules, powders, granules, tablets, sugar-coated tablets, syrups, pills, suspensions, liquids, emulsions, etc., and as parenteral injections, suppositories, topical skin preparations, etc. To achieve the objectives of the present invention, oral administration is preferred.

[0016] The present invention, characterized by containing acerola and isoproterenol, is a composition having bradycardia-improving and atrioventricular block-improving effects. Within limits that do not impair the effects, it may optionally contain excipients, stabilizers, lubricants, preservatives, binders, disintegrants, hydrocarbons, fatty acids, alcohols, esters, pH adjusters, preservatives, and fragrances commonly used in foods, quasi-drugs, or pharmaceuticals. Furthermore, it may contain plant materials, polyphenols, vitamins, sugars, proteins, and oils. In addition, the inclusion of akebi is particularly preferable in terms of enhancing the bradycardia-improving and atrioventricular block-improving effects. [Effects of the Invention]

[0017] The present invention provides a composition containing acerola and isoproterenol, which has bradycardia-improving and atrioventricular block-improving effects, and exhibits excellent bradycardia-improving and atrioventricular block-improving effects. MODE FOR CARRYING OUT THE INVENTION

[0018] The following examples are described for illustrative purposes, and the claims of the present invention are not limited in any way by these examples. The "%" for contents shown in the examples refers to % by weight. EXAMPLES

[0019] Production Example 1 Acerola fruit juice powder 1 kg of acerola fruit was squeezed to obtain 700 mL of fruit juice. 2 L of purified water was added to 500 mL of the obtained fruit juice, 0.8% yeast was added to the resulting fruit juice, and fermentation was carried out at 37°C for 30 hours. After fermentation, yeast removal and deactivation treatment were performed, 10 g of dextrin was added and dissolved. After dissolution, the mixture was spray-dried to obtain 20 g of acerola fruit juice powder.

[0020] Production Example 2 Hot water extract of acerola fruit 2 L of purified water was added to 100 g of acerola fruit, extraction was performed at 95 to 100°C for 2 hours, then the filtrate was concentrated and freeze-dried to obtain 9.6 g of a hot water extract of acerola fruit.

[0021] Production Example 3 30% ethanol extract of acerola fruit 1.4 L of purified water and 0.6 L of ethanol were added to 100 g of acerola fruit, extraction was performed at normal temperature for 5 days, then the filtrate was concentrated to dryness to obtain 2.4 g of a 30% ethanol extract of acerola fruit.

[0022] Production Example 4 50% ethanol extract of acerola fruit 1 L of purified water and 1 L of ethanol were added to 100 g of acerola fruit, extraction was performed at normal temperature for 5 days, then the filtrate was concentrated to dryness to obtain 2.1 g of a 50% ethanol extract of acerola fruit.

[0023] Next, formulation examples using acerola and isoproterenol are listed, but the present invention is not limited thereto. EXAMPLES

[0024] Formulation Example 1 Tablet <Prescription> Component Content (%) 1. Acerola juice powder (Manufacturing example 1) 2.0 2. Isoproterenol 2.0 3. Add maltitol so that the total amount becomes 100. 4. Cellulose 5.0 5. Sucrose fatty acid ester 3.0 <Manufacturing method> Components 1-4 were mixed, 10% water was added as a binder, and the mixture was granulated in a fluid bed. Component 5 was added to the formed granules and mixed, and then compressed into tablets to obtain 300 mg tablets. <Usage> Take 3 tablets per day.

[0025] Prescription Example 2: Hard Capsules <Prescription> Component Content (%) 1. Acerola fruit hot water extract (production example 2) 20.0 2. Isoproterenol 2.0 3. Sucrose fatty acid ester 3.0 4. Add cornstarch until the total amount is 100. <Manufacturing method> Components 1-4 were mixed and filled into No. 2 hard capsules with 250 mg each to obtain hard capsules. <Usage> Take two tablets per day.

[0026] Prescription Example 3: Soft Capsules <Prescription> Component Content (%) 1. Acerola juice powder (Manufacturing example 1) 0.2 2. Isoproterenol 2.0 3. Beeswax 5.0 4. Glycerin fatty acid ester 5.0 5. Vitamin E 3.0 6. Add medium-chain triglyceride oil until the total amount is 100. <Manufacturing method> Components 1-6 were mixed, and 250 mg of the mixture was filled into a coating composed of starch, carrageenan, reduced starch syrup, and glycerin. After drying, soft capsules were obtained. <Usage> Take 3 tablets per day. [Examples]

[0027] Test Example 1: Improvement of bradycardia and atrioventricular block Commercially available muscle cells were treated with 10 μM isoproterenol and acerola juice powder (Production Example 1) at concentrations of 10 μg / mL and 500 μg / mL, respectively. After 24 hours of incubation, gene expression analysis was performed. As indicators of improvement in bradycardia and atrioventricular block, the gene expression levels of FNDC5 and PGC1α, which increase with adrenergic receptor agonism, were compared. β-actin was used as the internal standard. Gene expression levels in cells without sample addition were set to 1, and the gene expression ratio was calculated.

[0028] Primer set for FNDC5 CAAAGAACAAAGATGAGGTGACCA(Sequence 1) TTCTCCTTGTTGTTATTGGGCT(Sequence 2) Primer set for PGC1α GATGGCACGCAGCCCTATT (array 3) CGACACGGAGAGTTAAAGGAAGA (array 4) Primer set for β-actin AGATGACCCAGATCATGTTTGAGA (Sequence 5) CACAGCCTGGATGGCTACGTA (sequence 6)

[0029] The results of Test Example 1 are shown in Table 1. In both FNDC5 and PGC1α, the increase in expression from the combination of acerola juice powder and isoproterenol was greater than the combined increase in expression from acerola juice powder alone and isoproterenol alone. [Table 1]

[0030] The results above demonstrate that acerola and isoproterenol synergistically enhance each other's effects, resulting in a more significant improvement in bradycardia and atrioventricular block compared to acerola or isoproterenol alone. Therefore, combining acerola with the existing drug isoproterenol allows acerola to enhance the effects of isoproterenol, enabling a similar level of efficacy with a lower dose of isoproterenol.

[0031] Furthermore, using the same method as in Test Example 1, we examined a group that combined acerola, isoproterenol, and akebi, and found that the combined expression increase was greater than the sum of the individual expression increases. This indicates that the combination of acerola, isoproterenol, and akebi shows particularly remarkable bradycardia-improving and atrioventricular block-improving effects. [Industrial applicability]

[0032] Based on the above, the present invention provides a composition containing acerola and isoproterenol, which has excellent bradycardia-improving and atrioventricular block-improving effects, and can be used as a food, quasi-drug, or pharmaceutical.

Claims

[Claim 1] A PGC1α production promoter in muscle cells, characterized by containing acerola and isoproterenol.

Citation Information

Patent Citations

  • Material treated with acerola containing polyphenol and / or vitamin c

    JP2011052028A

  • Blood glucose level suppressants and AGE formation inhibitors

    JP4451627B2

  • JPP7075694B